Adverse effects of highly active antiretroviral therapy in developing countries.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsWhy the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transitionRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirIncidence and predictors of first line antiretroviral regimen modification in western KenyaAccess and management of HIV-related diseases in resource-constrained settings: a workshop report.Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.The symptom experience of people living with HIV and AIDS in the Eastern Cape, South Africa.Magnitude of Antiretroviral Drug Toxicity in Adult HIV Patients in Ethiopia: A cohort study at seven teaching hospitals.Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings.Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in GhanaEvaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, NigeriaAn assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa.Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective StudyPredictors of Persistent Anaemia in the First Year of Antiretroviral Therapy: A Retrospective Cohort Study from Goma, the Democratic Republic of CongoHigher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentAdverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in NigeriaAdverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART RegimenNutritional status of HIV-infected patients during the first year HAART in two West African cohorts.Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.Association between nutritional status and the immune response in HIV + patients under HAART: protocol for a systematic review.Effectiveness and safety of concurrent use of first-line antiretroviral and antituberculous drugs in rwanda.Brief Report: Decentralizing ART Supply for Stable HIV Patients to Community-Based Distribution Centers: Program Outcomes From an Urban Context in Kinshasa, DRC.Anemia among adult HIV patients in Ethiopia: a hospital-based cross-sectional study.Prevalence, Correlates and Under-Diagnosis of Clinical Depression among Adults on Highly Active Antiretroviral Therapy in a Tertiary Health Institution in Northeastern Nigeria.Pharmacogenomics for infectious diseases in sub-Saharan Africa: Successes and opportunities.Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study.Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK HIV clinic.Health related quality of life of HIV/AIDS patients on highly active anti-retroviral therapy at a university referral hospital in Ethiopia.A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.Case histories of infectious disease management in developing countries: Phnom Penh and Kabul.Anemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia.Comparison of Zidovudine and Tenofovir Based Regimens With Regard to Health-Related Quality of Life and Prevalence of Symptoms in HIV Patients in a Kenyan Referral Hospital
P2860
Q28069383-72EE2509-456E-430C-8E77-DCA5397102D0Q28393479-6BB5C5D9-B0E4-4BD4-A000-A7277555DF3CQ28533242-67580480-6194-4FCF-9697-86F4E913C693Q28541822-147EE457-57FC-42D6-AB94-97A98649ADC0Q30387272-D6BF2333-1EE9-4363-9EC6-86DC6E9AA449Q33390898-61F5159A-823B-420B-8822-BFA7384DBDECQ33395119-EF44DAC3-FF76-41EB-9583-B797BA9DB0FDQ33596144-1A5BB3E2-9F42-4433-9F34-D451B4A66A2FQ33598309-2F5BC36B-C6EC-4074-9A47-E1B2DF02756CQ34174009-C33BF5E5-C668-4C0F-AD84-6CA0F060D6F0Q34347685-2E967815-8B92-48E6-A599-89D78A29AB47Q34427807-C69E1A99-3A8E-413D-9C70-30B698BCC5FCQ34670487-05906E64-F393-4E56-9FB8-01E7812971CFQ35104583-40612292-FA07-45BE-8C0D-E929DA4FD526Q35147717-4566A370-51FF-4091-AC64-5950F0003690Q36167659-BB65CAEC-3F62-4CD2-AFE1-41ACCFFB7834Q36170959-2E1290C1-C2DF-4E3D-8B85-B14C80633B5DQ36384257-18AAB53E-58F7-44AF-8254-A3F8A61C4183Q36979014-25722BEA-57FD-4F91-BE95-9C2E3D880D3AQ36993353-6613BB33-E3D2-4AE4-BD5C-B35059DEBAF6Q37166538-387D2DD0-05DE-4CBE-A074-3550187CDA99Q37261479-B2D29BC4-6808-458A-90B0-E968CCF8F81DQ37302739-DAE11459-7C2B-4B56-A2B6-188645667C00Q37453634-71E91D29-8864-4CC0-B0BB-8E6C6531C003Q37581308-C16F3932-1994-483C-ABC7-24ABA3341869Q37593420-18D11337-1DD2-4C7E-A47F-708D7C3133C2Q37639072-15DE0467-69FF-443D-972E-2AE667F164C7Q37652858-C250D9FD-E747-4957-A4A9-473679D6FC19Q37692882-9BBE0B04-AF8D-4BBB-851F-0609DB16551DQ40632449-1721BCF0-A481-4332-BEB4-4DB4EC2335EFQ41564295-683A15D8-D5C9-4610-8EEB-00940D5DE76AQ42152225-C4363642-D664-4B68-BA27-7DE33D2EF5A8Q42234057-DCBBC4E8-A5F4-402A-8D39-E9CA35993246Q42696007-30D11717-0DE1-4FFD-A879-D433C1517A5DQ43228891-7105DDA3-211E-4500-9FC1-83B86BBE866BQ45773759-57C2AC6C-93C4-477C-ADB4-D50A7D7A1D7DQ46830715-D95B6D43-18FB-46F4-9E29-C6533ADE7813Q51920941-7822BDC4-CE22-4F32-816D-8EB3F1683DF7Q53695386-5294FD99-294D-4C30-B109-42A8D7123C8EQ58122670-3AC4AA47-DF78-4EC5-BE47-FC0D30F3DBC7
P2860
Adverse effects of highly active antiretroviral therapy in developing countries.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adverse effects of highly active antiretroviral therapy in developing countries.
@en
type
label
Adverse effects of highly active antiretroviral therapy in developing countries.
@en
prefLabel
Adverse effects of highly active antiretroviral therapy in developing countries.
@en
P2093
P2860
P356
P1476
Adverse effects of highly active antiretroviral therapy in developing countries.
@en
P2093
Ramnath Subbaraman
Sreekanth Krishna Chaguturu
Timothy P Flanigan
P2860
P304
P356
10.1086/521150
P407
P577
2007-09-06T00:00:00Z